Inyx to Present at CEUT Emerging Growth Life Sciences Conference

NEW YORK, Oct. 20  /PRNewswire-FirstCall/ -- Inyx, Inc. (OTC:IYXI) (BULLETIN BOARD: IYXI) , a specialty pharmaceutical company with a focus on niche drug delivery technologies and products, will make a presentation at the Emerging Growth Life Sciences Conference sponsored by the New York investment firm C.E. Unterberg, Towbin.  The conference will be held next week at The Palace Hotel in New York City on October 25 & 26, 2005.

Inyx will present at 2:00 p.m. EDT on Tuesday, October 25.  The Inyx presentation will also be webcast live at: http://www.wsw.com/webcast/ceut3/iyxi.ob/ and the presentation will be archived for 90 days at that site as well as at Inyx's own website.

Inyx will also be available before and after its presentation on October 25 for meetings with investors attending the conference.  At the conference, Inyx will discuss several strategic growth initiatives that it has recently commenced and related updated financial guidance.

On September 8, 2005, Inyx and King Pharmaceuticals, Inc. (NYSE:KG) announced that they have entered into a long-term, strategic alliance that includes Inyx's first revenue-sharing deal with a client.  On August 31, 2005, Inyx announced completion of its strategic acquisition of Celltech Manufacturing Services Limited in Ashton, England (near Manchester), expanding Inyx's development and production capabilities into solid dose and injectable drug delivery as well as more extensive dry powder inhaler products, which broaden Inyx's abilities to serve the United Kingdom, Europe and Asia.  On March 31, 2005, Inyx completed its acquisition of certain assets and business of Aventis Pharmaceuticals Puerto Rico Inc. from sanofi-aventis Group (NYSE:SNY), providing Inyx with a strategic operating base in the United States.

About Inyx

Inyx, Inc. is a specialty pharmaceutical company with niche drug delivery technologies and products for the treatment of respiratory, allergy, dermatological, topical and cardiovascular conditions.  Inyx focuses its expertise on both prescription and over-the-counter pharmaceutical products, and provides specialty pharmaceutical development and production consulting services.  In addition, Inyx is developing its own proprietary products to be marketed by selected clients and strategic partners.  The company's operations are conducted through several wholly owned subsidiaries, including:  Inyx USA, Ltd., based in Manati, Puerto Rico; Inyx Pharma Limited, near Manchester, England; Inyx Europe Limited, also near Manchester; and Inyx Canada, Inc. in Toronto.  Inyx, Inc.'s corporate offices are in New York City.  For more information, please visit: http://www.inyxinc.com/.

Safe Harbor

Statements about Inyx's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995.  Inyx intends that such forward-looking statements be subject to the safe harbors created thereby.  Since these statements involve risks and uncertainties and are subject to change at any time, Inyx's actual results could differ materially from expected results.

  For more information, please contact:
  Jay M. Green, Executive VP
  Inyx, Inc.
  212-838-1111
  

DATASOURCE: Inyx, Inc.



CONTACT:  Jay M. Green, Executive VP of Inyx, Inc., [phone]





Web site:  http://www.inyxinc.com/

Copyright